Tezampanel

Tezampanel

Tezampanel is a pharmaceutical drug that was developed by the TorreyPines Therapeutics company. It is a non-competitive AMPA receptor antagonist, which means it works by inhibiting the action of the glutamate neurotransmitter on the AMPA receptor.

History

Tezampanel was initially developed as a potential treatment for stroke and migraine. In the early 2000s, it underwent Phase II clinical trials for these conditions. However, the development of the drug was discontinued in 2009 when TorreyPines Therapeutics ceased operations.

Mechanism of Action

Tezampanel works by blocking the action of glutamate, a neurotransmitter, on the AMPA receptor. Glutamate is the primary excitatory neurotransmitter in the nervous system, and it plays a key role in neural activation. By blocking the action of glutamate on the AMPA receptor, Tezampanel reduces neural activation, which can help to alleviate symptoms of conditions like stroke and migraine.

Clinical Trials

In the early 2000s, Tezampanel underwent Phase II clinical trials as a potential treatment for stroke and migraine. The results of these trials showed that the drug had a positive effect on reducing the severity and frequency of migraines. However, the development of the drug was discontinued before it could undergo Phase III trials.

Discontinuation

The development of Tezampanel was discontinued in 2009 when TorreyPines Therapeutics ceased operations. The company cited financial difficulties as the reason for its closure. Since then, no further development of Tezampanel has been reported.

See Also

• AMPA receptor
• Glutamate (neurotransmitter)
• Stroke
• Migraine

This article is a stub related to pharmacology. You can help WikiMD by expanding it!